All In Biotech

Drug Trial Radar · NCT06205628

Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ADX-850 in Participants With Hypertension

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

28

Actual

Start

Mar 21, 2024

Primary completion

Oct 6, 2026

Study completion Mar 31, 2027

Sponsor

Lead sponsor
ADARx Pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
ADARx Australia Pty Ltd
First posted
Jan 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-850 in participants with hypertension.

Conditions

  • Hypertension
  • Hypertension,Essential

Interventions

  • ADX-850Drug

    siRNA duplex oligonucleotide

  • PlaceboDrug

    Saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of ADX-850 in Participants with HypertensionTime frame: 365 days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Clinitrials Pty Ltd

    Perth, Australia

  • CMAX Clinical Research

    Adelaide, South Australia, Australia

  • Linear Clinical Research

    Nedlands, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.